Can Longitudinal Biomarkers Guide Treatment Decisions? Time Will Tell

Clin Cancer Res. 2025 Apr 14;31(8):1381-1382. doi: 10.1158/1078-0432.CCR-24-4297.

Abstract

Defining patterns of acquired resistance has important prognostic and therapeutic implications in patients with lung cancer. Longitudinal biomarker analysis has enhanced our understanding of tumor biology and treatment response. However, the role of temporally informed biomarkers in guiding clinical decisions, such as local therapy intervention, remains unproven. See related article by Mazzaschi et al., p. 1533.

MeSH terms

  • Biomarkers, Tumor* / genetics
  • Clinical Decision-Making*
  • Drug Resistance, Neoplasm
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / therapy
  • Prognosis

Substances

  • Biomarkers, Tumor